VTRS Viatris Inc.
USHealthcareAs of 2026-07-09 16:00
Why VTRS matters now
Viatris Inc. (VTRS) is a US stock in Healthcare. The latest InvestLog snapshot shows $16.34 with -1.92% on the session and $19.03B in market capitalization; recent performance reads 1-month -4.95% and YTD +23.45%.
The latest financial table shown here is Q1 2026, with revenue of $3.52B, net income of $176.4M, and EPS of $0.15. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield 9.6%.
The latest indexable market news headline is "VTRS or DHR: Which Is the Better Value Stock Right Now?" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Hold with a median target of $18.00; recent insider activity includes Le Goff Corinne filing M-Exempt. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.21
P/S
1.23
EV/EBITDA
11.87
DCF Value
$23.62
FCF Yield
9.6%
Div Yield
3.1%
Margins & Returns
Gross Margin
34.4%
Operating Margin
1.0%
Net Margin
-2.0%
ROE
-2.0%
ROA
-0.8%
ROIC
0.2%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $3.52B | $176.4M | $0.15 |
| Q4 2025 | $3.70B | $-340.1M | $-0.30 |
| FY 2025 | $14.30B | $-3.51B | $-3.00 |
| Q3 2025 | $3.76B | $-128.2M | $-0.11 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$17.40
Target (Median)
$18.00
Target Range
$12.00 - $22.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
US
Exchange
—
Beta
0.90
Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.